Who are our partners
Physicians and healthcare networks
use MH Guide to bring precision medicine to their patients. The comprehensive evaluation summarized in an MH Guide report allows physicians to leverage the unique genomics of a patient’s tumor to find more effective and tolerable therapies. Complex cases are often referred to a molecular tumor board. There, a multidisciplinary team assesses all available information to make a treatment recommendation. MH Guide supports those discussions with clearly presented variants detected in a case, the clinical relevance of those variants based on authoritative guidelines, a list of recommended therapies with approval status, and high-quality matching to ongoing clinical trials.
benefit from the IVDR certification of MH Guide to quickly and accurately interpret and report on next-generation sequencing (NGS) test results. Combining data from the powerful and continuously updated knowledge base Dataome with a validated process for analyzing NGS data, MH Guide identifies and reports on clinically significant germline variants associated with hereditary cancers and somatic tumor mutations that guide treatment choices. The MH VCF Adapter Suite allows users to seamlessly adapt output data from different variant detection pipelines and process it with MH Guide – regardless of the used sequencing platform.
Pharma and biotech companies
tackle increasing pressure to deliver innovative and successful drugs faster and with reduced costs with our Dataome technology. Harnessing the power of artificial intelligence, machine learning, big data, and subject matter expertise, they advance their drug development programs with data-driven decisions to identify successful drug candidates and optimize clinical trial designs, all while increasing cost efficiency. Our services empower partners to uncover new target-disease relationships, reveal promising targets for the development of novel therapies, and provide greater insights into patient populations that respond to treatments.
Biomedical and clinical researchers
are increasingly using big data to uncover the causes of diseases. In collaboration with our data analytics experts, our partners identify relevant clinico-molecular data in Dataome and use sophisticated algorithms and machine learning techniques to reveal patterns and correlations among parameters of diseases. Examples of these collaborative efforts include a whole-patient model of COVID-19 symptomatology, a strategy to use real-world data and clinico-molecular data to reveal mechanisms of drug toxicity, and the prediction of upregulated miRNA species during COVID-19 disease progression.
What they say
With head offices in Bonn, Germany, GENOPATH GbR is an association of 16 pathology institutes. The group was formed to supply all member laboratories with top-quality and cutting-edge molecular diagnostic services that complement existing histological and cytological methods, making comprehensive care available to every cancer patient.
OncoNet Rhine-Main e. V.
The OncoNet Rhine-Main is a network of clinics, molecular pathology laboratories, practices and medical centers that aims to provide effective and targeted care to all cancer patients in the Rhein-Main area. Working together, partners in the network support clinical studies to integrate innovative therapy approaches into daily clinical practice.
Charité Institute of Pathology
The Institute of Pathology at the Charité Berlin is a key player in the care of cancer patients of the country’s capital and surrounding area. Their broad spectrum of analytical methods covers histological, cytological, and molecular diagnostics to deliver the reliable and timely identification of therapeutic options.
Gen Era Diagnostics
Gen Era Diagnostics is a leading provider of molecular diagnostics products and services in Turkey. The company has empowered scientists, clinicians, and laboratories in the investigation of diseases and the treatment of patients since 2013 with a comprehensive offering of cutting-edge research and diagnostic technologies.